Deferiprone or fatal iron toxic effects? [2]

Lancet

Volumn 357, Issue 9259, 2001, Pages 882-883

  Kontoghiorghes, G J ^a   Agarwal, M B ^b   Tondury, P ^b   Marx, J J M ^b  

^a Postgraduate Research Institute Science Technology Environment and Medicine   (Cyprus)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM DERIVATIVE; CALCIUM DISODIUM PENTETAC; DEFERIPRONE; DEFEROXAMINE; IRON CHELATE; ORPHAN DRUG; UNCLASSIFIED DRUG;

CHELATION THERAPY; DRUG COST; DRUG EFFECT; HUMAN; IRON CHELATION; IRON OVERLOAD; LETTER; LIVER FIBROSIS; LIVER TOXICITY; PRIORITY JOURNAL; THALASSEMIA;

EID: 0035901252     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)71812-2     Document Type: Letter

References (5)

1. Deferiprone for thalassaemia
2. Long term safety and effectiveness of iron chelation therapy with deferiprone for thalassaemia major
3. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1)
4. Oral chelation in the treatment of thalassaemia and other diseases
5. Iron chelation using subcutaneous infusion of diethylene triamine penta-acetic acid (DTPA)